You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT JAMA
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 290 No. 8, August 27, 2003 TABLE OF CONTENTS
  JAMA
  •  Online Features
  Original Contribution
 This Article
 •Full text
 •PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on ISI (101)
 •Contact me when this article is cited
 Related Content
 •Related letter
 •Related articles
 •Similar articles in JAMA
 Topic Collections
 •Neurology
 •Stroke
 •Arrhythmias
 •Alert me on articles by topic

A Risk Score for Predicting Stroke or Death in Individuals With New-Onset Atrial Fibrillation in the Community

The Framingham Heart Study

Thomas J. Wang, MD; Joseph M. Massaro, PhD; Daniel Levy, MD; Ramachandran S. Vasan, MD; Philip A. Wolf, MD; Ralph B. D'Agostino, PhD; Martin G. Larson, ScD; William B. Kannel, MD; Emelia J. Benjamin, MD, ScM

JAMA. 2003;290:1049-1056.

Context  Prior risk stratification schemes for atrial fibrillation (AF) have been based on randomized trial cohorts or Medicare administrative databases, have included patients with established AF, and have focused on stroke as the principal outcome.

Objective  To derive risk scores for stroke alone and stroke or death in community-based individuals with new-onset AF.

Design, Setting, and Participants  Prospective, community-based, observational cohort in Framingham, Mass. We identified 868 participants with new-onset AF, 705 of whom were not treated with warfarin at baseline. Risk scores for stroke (ischemic or hemorrhagic) and stroke or death were developed with censoring when warfarin initiation occurred during follow-up. Event rates were examined in low-risk individuals, as defined by the risk score and 4 previously published risk schemes.

Main Outcome Measures  Stroke and the combination of stroke or death.

Results  During a mean follow-up of 4.0 years free of warfarin use, stroke alone occurred in 83 participants and stroke or death occurred in 382 participants. A risk score for stroke was derived that included the following risk predictors: advancing age, female sex, increasing systolic blood pressure, prior stroke or transient ischemic attack, and diabetes. With the risk score, 14.3% of the cohort had a predicted 5-year stroke rate <=7.5% (average annual rate <=1.5%), and 30.6% of the cohort had a predicted 5-year stroke rate <=10% (average annual rate <=2%). Actual stroke rates in these low-risk groups were 1.1 and 1.5 per 100 person-years, respectively. Previous risk schemes classified 6.4% to 17.3% of subjects as low risk, with actual stroke rates of 0.9 to 2.3 per 100 person-years. A risk score for stroke or death is also presented.

Conclusion  These risk scores can be used to estimate the absolute risk of an adverse event in individuals with AF, which may be helpful in counseling patients and making treatment decisions.


Author Affiliations: Framingham Heart Study, Framingham (Drs Wang, Massaro, Levy, Vasan, Wolf, D'Agostino, Larson, Kannel, and Benjamin); Cardiology Division, Massachusetts General Hospital, Harvard Medical School (Dr Wang); Divisions of Cardiology and Epidemiology, Beth Israel Deaconess Hospital, Harvard Medical School (Dr Levy); Department of Mathematics, Boston University (Drs Massaro and D'Agostino), Boston; National Heart, Lung, and Blood Institute, Bethesda, Md (Dr Levy); and Department of Neurology (Dr Wolf), Division of Cardiology (Drs Levy, Vasan, and Benjamin), and Department of Preventive Medicine (Drs Levy, D'Agostino, Wolf, Kannel, and Benjamin), Boston University School of Medicine, Boston.


RELATED LETTER

Age and Sex as Independent Risk Factors for Stroke Among Patients With Atrial Fibrillation
Yujiro Kida
JAMA. 2003;290(22):2937.
EXTRACT | FULL TEXT  

RELATED ARTICLES

Stroke Prevention in Atrial Fibrillation
Albert L. Waldo
JAMA. 2003;290(8):1093-1095.
EXTRACT | FULL TEXT  

Atrial Fibrillation
Sharon Parmet, Cassio Lynm, and Richard M. Glass
JAMA. 2003;290(8):1118.
EXTRACT | FULL TEXT  


THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Antithrombotic Therapy in Atrial Fibrillation: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)
Singer et al.
Chest 2008;133:546S-592S.
ABSTRACT | FULL TEXT  

Comparison of 12 Risk Stratification Schemes to Predict Stroke in Patients With Nonvalvular Atrial Fibrillation
Stroke Risk in Atrial Fibrillation Working Group
Stroke 2008;39:1901-1910.
ABSTRACT | FULL TEXT  

Comparison of Risk Stratification Schemes to Predict Thromboembolism in People With Nonvalvular Atrial Fibrillation
Fang et al.
J Am Coll Cardiol 2008;51:810-815.
ABSTRACT | FULL TEXT  

Quality of Anticoagulation Monitoring in Nonvalvular Atrial Fibrillation Patients: Comparison of Anticoagulation Clinic versus Usual Care
Nichol et al.
The Annals of Pharmacotherapy 2008;42:62-70.
ABSTRACT | FULL TEXT  

ASHP Therapeutic Position Statement on Antithrombotic Therapy in Chronic Atrial Fibrillation
Nutescu
Am J Health Syst Pharm 2007;64:2281-2291.
FULL TEXT  

Risk factors for anticoagulation-related bleeding complications in patients with atrial fibrillation: a systematic review
Hughes et al.
QJM 2007;100:599-607.
ABSTRACT | FULL TEXT  

Can Patients at Elevated Risk of Stroke Treated With Anticoagulants Be Further Risk Stratified?
Baruch et al.
Stroke 2007;38:2459-2463.
ABSTRACT | FULL TEXT  

Independent predictors of stroke in patients with atrial fibrillation: A systematic review
The Stroke Risk in Atrial Fibrillation Working Gro
Neurology 2007;69:546-554.
ABSTRACT | FULL TEXT  

A Cautionary Note on Data Sources for Evidence-Based Clinical Decisions: Warfarin and Stroke Prevention
Thomson et al.
Med Decis Making 2007;27:438-447.
ABSTRACT  

Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: full text: The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD)
Authors/Task Force Members et al.
Eur Heart J Suppl 2007;9:C3-C74.
FULL TEXT  

Blood Pressure and Estimated Risk of Stroke in the Elderly Population of Spain: The PREV-ICTUS Study
Redon et al.
Stroke 2007;38:1167-1173.
ABSTRACT | FULL TEXT  

Mortality Trends in Patients Diagnosed With First Atrial Fibrillation: A 21-Year Community-Based Study
Miyasaka et al.
J Am Coll Cardiol 2007;49:986-992.
ABSTRACT | FULL TEXT  

Gender-Related Differences in Presentation, Treatment, and Outcome of Patients With Atrial Fibrillation in Europe: A Report From the Euro Heart Survey on Atrial Fibrillation
Dagres et al.
J Am Coll Cardiol 2007;49:572-577.
ABSTRACT | FULL TEXT  

Advances in Surgical Treatment of Atrial Fibrillation
Gillinov
Stroke 2007;38:618-623.
ABSTRACT | FULL TEXT  

Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary: The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD)
Authors/Task Force Members et al.
Eur Heart J 2007;28:88-136.
FULL TEXT  

Antithrombotic treatment in real-life atrial fibrillation patients: a report from the Euro Heart Survey on Atrial Fibrillation
Nieuwlaat et al.
Eur Heart J 2006;27:3018-3026.
ABSTRACT | FULL TEXT  

ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: full text: A report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation) Developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society
Writing Committee Members et al.
Europace 2006;8:651-745.
FULL TEXT  

ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation) Developed in Collaboration With the European Heart Rhythm Association and the Heart Rhythm Society
Fuster et al.
J Am Coll Cardiol 2006;48:e149-e246.
FULL TEXT  

ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): Developed in Collaboration With the European Heart Rhythm Association and the Heart Rhythm Society
Fuster et al.
Circulation 2006;114:e257-e354.
FULL TEXT  

Anticoagulation in women with non-valvular atrial fibrillation in the stroke prevention using an oral thrombin inhibitor (SPORTIF) trials
Gomberg-Maitland et al.
Eur Heart J 2006;27:1947-1953.
ABSTRACT | FULL TEXT  

Anticoagulation for stroke prevention in atrial fibrillation: is gender important?
Lip et al.
Eur Heart J 2006;27:1893-1894.
FULL TEXT  

Relationship of Atrial Fibrillation and Stroke After Coronary Artery Bypass Graft Surgery: When is Anticoagulation Indicated?
Kollar et al.
Ann. Thorac. Surg. 2006;82:515-523.
ABSTRACT | FULL TEXT  

Primary Prevention of Ischemic Stroke: A Guideline From the American Heart Association/American Stroke Association Stroke Council: Cosponsored by the Atherosclerotic Peripheral Vascular Disease Interdisciplinary Working Group; Cardiovascular Nursing Council; Clinical Cardiology Council; Nutrition, Physical Activity, and Metabolism Council; and the Quality of Care and Outcomes Research Interdisciplinary Working Group: The American Academy of Neurology affirms the value of this guideline.
Goldstein et al.
Circulation 2006;113:e873-e923.
ABSTRACT | FULL TEXT  

Modelling the health benefits and economic implications of implanting dual-chamber vs. single-chamber ventricular pacemakers in the UK
Caro et al.
Europace 2006;8:449-455.
ABSTRACT | FULL TEXT  

Primary Prevention of Ischemic Stroke: A Guideline From the American Heart Association/American Stroke Association Stroke Council: Cosponsored by the Atherosclerotic Peripheral Vascular Disease Interdisciplinary Working Group; Cardiovascular Nursing Council; Clinical Cardiology Council; Nutrition, Physical Activity, and Metabolism Council; and the Quality of Care and Outcomes Research Interdisciplinary Working Group: The American Academy of Neurology affirms the value of this guideline.
Goldstein et al.
Stroke 2006;37:1583-1633.
ABSTRACT | FULL TEXT  

Biomarkers of Cardiovascular Disease: Molecular Basis and Practical Considerations
Vasan
Circulation 2006;113:2335-2362.
FULL TEXT  

Translating Clinical Research into Clinical Practice: Impact of Using Prediction Rules To Make Decisions
Reilly and Evans
ANN INTERN MED 2006;144:201-209.
ABSTRACT | FULL TEXT  

Evaluation of survival and ischaemic and thromboembolic event rates in patients with non-valvar atrial fibrillation in the general population when treated and untreated with warfarin
Currie et al.
Heart 2006;92:196-200.
ABSTRACT | FULL TEXT  

Time Trends of Ischemic Stroke Incidence and Mortality in Patients Diagnosed With First Atrial Fibrillation in 1980 to 2000: Report of a Community-Based Study
Miyasaka et al.
Stroke 2005;36:2362-2366.
ABSTRACT | FULL TEXT  

Perindopril-Based Blood Pressure-Lowering Reduces Major Vascular Events in Patients With Atrial Fibrillation and Prior Stroke or Transient Ischemic Attack
Arima et al.
Stroke 2005;36:2164-2169.
ABSTRACT | FULL TEXT  

Gender Differences in the Risk of Ischemic Stroke and Peripheral Embolism in Atrial Fibrillation: The AnTicoagulation and Risk factors In Atrial fibrillation (ATRIA) Study
Fang et al.
Circulation 2005;112:1687-1691.
ABSTRACT | FULL TEXT  

A trial of self-adhesive patch electrodes and hand-held paddle electrodes for external cardioversion of atrial fibrillation (MOBIPAPA)
Kirchhof et al.
Eur Heart J 2005;26:1292-1297.
ABSTRACT | FULL TEXT  

Effects of congestive heart failure on plasma von Willebrand factor and soluble P-selectin concentrations in patients with non-valvar atrial fibrillation
Lip et al.
Heart 2005;91:759-763.
ABSTRACT | FULL TEXT  

In defence of current treatment options: where are we now?
Voller
Eur Heart J Suppl 2005;7:E4-E9.
FULL TEXT  

Economic factors associated with antithrombotic treatments for stroke prevention in patients with atrial fibrillation
Miller et al.
Eur Heart J Suppl 2005;7:C41-C54.
ABSTRACT | FULL TEXT  

Evaluation of the pattern of treatment, level of anticoagulation control, and outcome of treatment with warfarin in patients with non-valvar atrial fibrillation: a record linkage study in a large British population
Jones et al.
Heart 2005;91:472-477.
ABSTRACT | FULL TEXT  

New Frontiers in Interventional Cardiology
Sousa et al.
Circulation 2005;111:671-681.
FULL TEXT  

Emerging Role of Direct Thrombin Inhibitors in Nonvalvular Atrial Fibrillation: Potential and Peril
Kim and Arora
J CARDIOVASC PHARMACOL THER 2005;10:11-21.
ABSTRACT  

Selecting Patients With Atrial Fibrillation for Anticoagulation: Stroke Risk Stratification in Patients Taking Aspirin
Gage et al.
Circulation 2004;110:2287-2292.
ABSTRACT | FULL TEXT  

Antithrombotic Therapy in Atrial Fibrillation: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy
Singer et al.
Chest 2004;126:429S-456S.
ABSTRACT | FULL TEXT  

Recent trials in atrial fibrillation: lessons learned beyond rate and rhythm
Bode
Eur Heart J Suppl 2004;6:B15-B19.
ABSTRACT | FULL TEXT  

Age and Sex as Independent Risk Factors for Stroke Among Patients With Atrial Fibrillation
Kida
JAMA 2003;290:2937-2937.
FULL TEXT  

Anticoagulation Therapy for Stroke Prevention in Atrial Fibrillation: How Well Do Randomized Trials Translate Into Clinical Practice?
Go et al.
JAMA 2003;290:2685-2692.
ABSTRACT | FULL TEXT  

Should I start all my ischaemic stroke and TIA patients on a statin, an ACE inhibitor, a diuretic, and aspirin today?
Sandercock
J. Neurol. Neurosurg. Psychiatry 2003;74:1461-1464.
FULL TEXT  

JournalScan
Malik
Heart 2003;89:1373-1374.
FULL TEXT  

Predicting Stroke in Patients with New-Onset Afib in the Community
Journal Watch Cardiology 2003;2003:2-2.
FULL TEXT  

A 60-Year-Old Woman With Atrial Fibrillation
Singer
JAMA 2003;290:2182-2189.
FULL TEXT  

Stroke Prevention in Atrial Fibrillation
Waldo
JAMA 2003;290:1093-1095.
FULL TEXT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2003 American Medical Association. All Rights Reserved.